Preclinical research with autologous bone marrow transplantation has been performed in two models of autoimmune disease using Buffalo rats. In this strain, adjuvant arthritis develops as a chronic progressive systemic type of arthritis and experimental allergic encephalomyelitis as a chronic remitting relapsing disease. In these models, the influence of various treatment parameters was studied, among them the conditioning regimen, the composition of the graft and the effect of reimmunization of cured animals. Continued research in animal models is recommended to solve problems that have emerged from the experience with several hundreds of severely ill autoimmune patients treated thus far with autologous stem cells.
The pivotal role of the hematopoietic system in autoimmune diseases (AID) was brought to light by studies using hematopoietic radiation chimeras between rodent strains that are susceptible or resistant to various AID (reviewed by Van Bekkum 1 ). Whether these chimeric animals develop AID is generally dictated by the genotype of the bone marrow (BM). These observations gave rise to the hypothesis that the underlying defect of AID resides in the hematopoietic stem cell (HSC) [2] .
The animal models of AID fall into two distinct categories: the hereditary or spontaneous AID and the induced ones. In the first category, the disease develops with age in most if not all animals of the susceptible strain. These models include systemic lupus erythematosus (SLE)-like syndromes in mice, insulin-dependent diabetes in mice and rats, and a complex syndrome of arthritis/colitis/ dermatitis in HLA-B27 transgenic rats. Genetic factors dominate the pathogenesis of these diseases. The AID of the second category do not develop spontaneously, but require induction by immunization with specific tissues, for example, brain in the case of experimental allergic encephalomyelitis (EAE), which serves as a model for multiple sclerosis (MS), with tissue components like collagen (arthritis) or with bacterial antigens like Mycobacillus tuberculosis (adjuvant arthritis (AA)). In laboratory rodents, these diseases can only be induced in certain inbred strains. Susceptibility and resistance to induction are largely genetically determined, as demonstrated by crossbreeding, but environmental influences also play a role. Some AID such as arthritis and EAE can be induced in outbred animals like subhuman primates.
The etiology of human AID is multifactorial, the dominant contributing factors being genetic as well as environmental. Thus, it is likely that the inducible AID represent the more appropriate animal models for preclinical investigations. The curative potential of autologous bone marrow transplantation (BMT) was discovered in rats with induced arthritis and induced EAE.
Response of fully developed AID to allogeneic BMT
The experiments with hematopoietic chimeras described above had a logical sequel in attempts to cure animals with overt AID by replacing their BM with that from an allogeneic donor of a normal or a noninducible strain. The myelo-and lymphoablation that is required to achieve complete allogeneic chimerism is also highly effective in reducing the burden of autoreactive lymphocytes. Accordingly, allogeneic BMT after high-dose total body irradiation (TBI) was found to cure hereditary as well as inducible forms of AID.
Following these publications (reviewed by Van Bekkum 3 ), the hospital records of long-term survivors of allogeneic BMT -employed to treat a hematological malignancy or aplastic anemia -were searched for patients with coexisting AID at the time of the transplantation. A total of 21 patients were retrieved, comprising a wide range of AID, all of whom went into complete remission of their AID. 4, 5 And interestingly, aplastic anemia is itself an AID that is being treated successfully with allogeneic BMT since several decades. However, the substantial problems and the risks associated with allogeneic BMT precluded its application in the treatment of patients with refractory AID. As regards the use of autologous BM, concepts prevailing at that time about the pathogenesis of AID did not foster the idea that this might be effective. It was therefore a complete surprise when rats with AA responded just as well to autologous and to syngeneic BMT as to grafting with allogeneic BM. 6 
Clinical application of autologous BMT
The lower risks associated with autologous transplants justified a tryout of this approach in patients with severe AID, who were refractory to current treatments. Additional justification came from publications 7 that revealed a very poor life expectancy of subgroups of patients with progressive refractory rheumatic disease. The clinical studies on autologous BMT are essentially translated from our findings in animal models such as AA or EAE. These two models have a lot in common as regards the responses to treatment, but there are also considerable differences. In trying to translate these results to the clinic, one may elect to strictly adhere to the disease specificities, for example, apply the results with the AA model to treatment strategies for RA and those obtained with EAE for MS. The other way to utilize the results is to select from each model the parameters that seem to be most decisive for the outcome and to apply these to several clinical protocols until experience shows otherwise. Either strategy is subject to the restrictions imposed by the infidelities and peculiarities of the models.
Responses of rats with AID to autologous BMT
Both AA and EAE were induced in rats of the inbred Buffalo strain. These animals develop a chronic progressive systemic arthritis and a chronic remitting/relapsing EAE, respectively. In both diseases, high-dose TBI (9-10 Gy) followed by autologous BMT induces responses in all animals. 6, 8 In AA, 70% are complete responders and 30% partial responders. Both spontaneous and induced relapses are extremely rare in AA following high-dose TBI, but do occur after conditioning with cyclophosphemid (CY). 9 Rats with clinical EAE as manifested by paralysis and/or paresis respond to high-dose TBI and autologous BMT with a rapid complete regression of the neurological symptoms, but one or more spontaneous relapses occur in 30% of the animals. 8 Reimmunization at the time that most animals have recovered from their last spontaneous relapse, reinduces disease in 70% of the animals. When syngeneic BM instead of autologous BM is used to treat EAE, the spontaneous relapse rate is the same, 10 indicating that these relapses are caused by autoreactive cells that survived the conditioning, in other words they are due to residual autoimmune disease. Accordingly, T-cell depletion of the graft did not diminish the spontaneous relapse rate. This does not imply that the composition of the autologous graft -especially of its lymphocyte components -is irrelevant. On the contrary, following the addition of large numbers of autologous spleen cells to the BM graft, the spontaneous relapse rate of EAE rose to over 90%. In translating these findings to the clinical situation, it has to be kept in mind that the T-cell content of rat BM is 10 times less than that of human BM.
In both models, the best results have been obtained with the strongest lympho-myeloablative regimens that is, a supralethal dose of TBI or a combination of a lower TBI dose and CY.
Irradiation of the affected tissues only (the CNS in the case of EAE, or the legs in the case of AA) or shielding of those tissues while the rest of the body was irradiated, resulted at best in limited and temporary remissions. 6, 10 Fractionated TBI was studied in the AA model and proved to be as effective as single-dose TB, provided the total radiation dose was properly adjusted upwards. 9 In both AA and EAE, conditioning with CY alone or busulfan (BU) alone at highest tolerated doses was clearly inferior. A combination of CY and BU was nearly as effective as highdose TBI. The combination of a lower dose of TBI (4 Gy) with CY (2 Â 60 mg/kg) was equally effective as the highest dose of TBI. 9 The remarkable features of CY when used as the sole conditioning agent in AA were not only the lower rate of complete remissions, but also the substantial incidence (36%) of spontaneous relapses. In contrast, among 155 AA animals treated with high-dose TBI or with the combination regimens, only one relapse occurred.
Clinical relevance of the observations in experimental AID
The impressive results obtained with high-dose lympomyeloablative conditioning regimens are in accordance with the current concept of AID as being maintained by activated T cells. These have to be eliminated as thoroughly as possible to achieve complete and lasting remission. The experiments with animals are equivocal in demonstrating that treatment with lower doses of the various cytotoxic agents results in incomplete responses and more relapses. It is therefore unlikely that the so-called nonmyeloablative conditioning will be useful, unless the proportion of T cells destroyed by the use of new, more T-cell-specific agents, matches that of current myeloablative regimens.
Our finding that CY as the sole conditioning agent is less effective than high-dose TBI, or the combination regimens, implies that less lymphoreduction is achieved with CY. With regard to the prevention of relapses, it is generally believed that memory T cells are instrumental in causing relapses. There is some experimental evidence that memory T cells are more sensitive to ionizing radiation than to CY. Clinical experience with allogeneic BMT for treating aplastic anemia is that a high engraftment failure rate is observed in polytransfused patients following conditioning with CY only -presumably because of the presence of larger numbers of memory T cells. Yet, many clinicians prefer the use of CY alone or combined with ALG for conditioning of AID patients who are likely to harbor huge numbers of memory cells. Transplant doses of CY with ATG especially when combined with CY mobilization appears particularly effective in SLE, but relapses are high from this regimen in rheumatoid arthritis indicating that like AA, RA requires a more intense regimen such as busulfex and CY. TBI is disfavored in RA, mainly because it increases the risk of cancer. However, alkylating drugs like CY are also carcinigenic, as is the case for prolonged treatment with immunosuppressive agents.
Mechanism of the therapeutic effect of autologous BMT
How to explain the excellent results with autologous stem cells in our animal models and the encouraging results obtained thus far with this modality in patients? The current hypothesis is that the reconstitution of the immune system from a few HSCs represents a recapitulation of ontogenesis with the concomitant development of selftolerance. This theory is based mainly on the experience with grafting of purified allogeneic stem cells, which may lead to full immunological reconstitution in the absence of graft-versus-host disease.
Depending upon the disease, the most intensive conditioning appears to give the lowest relapse rate because it eliminates the highest proportion of autoreactive T lymphocytes. It stands to reason that this effect will be undone if the T cells in the autograft outnumber those surviving in the patient. A rough estimate of the surviving fraction is available only for TBI, that is, between 0.1 and 0.01% for the most effective dose, that is, 9-10 Gy.
11 As a result of these uncertainties, it seemed prudent to begin the clinical studies with maximally depleted autografts. The recommendation to graft no more that 10 5 T cells/kg 12 was based on the capabilities of current CD34 + cell selection techniques. However, these methods also remove B cells, NK cells and macrophages, which is unnecessary and possibly harmful. Such rigorous depletion may result in a prolonged period of severe immunosuppression with risks of infections and lymphoproliferative malignancies. Our data from the most sensitive model (EAE) suggest that 2 Â 10 6 T cell/kg would still be safe and this level of depletion should preferably be achieved by specific depletion of T lymphocytes.
Allogeneic compared to autologous BMT
Finally, there is the option of using matched allogeneic stem cells, which in the EAE rat minimize relapses because of its graft-versus-autologous T-cell effect. 13 Considering the higher risks of transplantation-associated mortality, the clinical exploration of allogeneic BMT should probably proceed cautiously until it becomes clear from the ongoing studies as to which category of patients do not benefit sufficiently from autologous stem cell transplants. This holds specifically for MS patients, as our data in the EAE model show both matched and mismatched allogeneic BMT to be superior to autologous BMT in greatly reducing the incidence of relapses.
14 For the treatment of connectivetissue-type AID however, allogeneic stem cells cannot be recommended because graft-versus-host reactions are very difficult to differentiate from symptoms caused by (a relapse of) the original AID.
It has been suggested that the induction of mixed allogeneic chimerism might be an attractive option by virtue of a graft-versus-autoimmunity effect in the absence of toxicity and graft-versus-host disease. Such approach might imply the use of a non-myeloablative conditioning and donor lymphocyte infusions. Apart from the problem that the induction of mixed chimerism in patients is as yet far from standardized, this approach should also be undertaken cautiously. In fact, our results with mixed chimeras in EAE revealed very high incidence of relapses. 14 
